BioCentury
ARTICLE | Clinical News

DB959: Phase I data

November 22, 2010 8:00 AM UTC

A double-blind, U.S. Phase I trial in 76 healthy volunteers showed that single ascending-doses of oral DB959 exhibited a safety profile comparable to that of placebo, with no moderate, severe or serio...